Changing landscape of frontline therapy in chronic lymphocytic leukemia

被引：2

作者：

Bhat, Seema A. ^{[1
]}

Woyach, Jennifer A. ^{[1
]}

机构：

[1] Ohio State Univ, Comprehens Canc Ctr, 455D Wiseman Hall CCC,410 W 12th Ave, Columbus, OH 43210 USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 03期

关键词：

Frontline therapy; CLL; chronic lymphocytic leukemia; BRUTONS TYROSINE KINASE; PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; OPEN-LABEL; FCR CHEMOIMMUNOTHERAPY; INITIAL THERAPY; PHASE-III; IBRUTINIB; RITUXIMAB; VENETOCLAX;

D O I：

10.1080/10428194.2019.1688321

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-cell receptor signaling pathway plays a central role in the pathogenesis of chronic lymphocytic leukemia. The advent of novel small-molecule therapy for the treatment of chronic lymphocytic leukemia targeting the B-cell receptor signaling pathway has dramatically changed the therapeutic landscape with recent studies establishing ibrutinib, a Bruton's tyrosine kinase inhibitor, as the frontline treatment of choice regardless of patient's age, performance status or risk-category. Although these current advances along with the approval of other newer agents for the treatment of chronic lymphocytic leukemia is a significant step forward, newer challenges have emerged on how to best utilize these new treatment options.

引用

页码：525 / 535

页数：11

共 68 条

[21]

Davids MS, 2017, BLOOD, V130

[22] Bruton's tyrosine kinase and phospholipase Cγ2 mediate chemokine-controlled B cell migration and homing [J].

de Gorter, David J. J. ;

Beuling, Esther A. ;

Kersseboom, Rogier ;

Middendorp, Sabine ;

van Gils, Janine M. ;

Hendriks, Rudolf W. ;

Pals, Steven T. ;

Spaargaren, Marcel .

IMMUNITY, 2007, 26 (01) :93-104

[23] Survival response to B-Cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression [J].

Deglesne, Pierre-Antoine ;

Chevallier, Nathalie ;

Letestu, Remi ;

Baran-Marszak, Fanny ;

Beitar, Taoufik ;

Salanoubat, Celia ;

Sanhes, Laurence ;

Nataf, Joelle ;

Roger, Claudine ;

Varin-Blank, Nadine ;

Ajchenbaum-Cymbalista, Florence .

CANCER RESEARCH, 2006, 66 (14) :7158-7166

[24] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial [J].

Eichhorst, Barbara ;

Fink, Anna-Maria ;

Bahlo, Jasmin ;

Busch, Raymonde ;

Kovacs, Gabor ;

Maurer, Christian ;

Lange, Elisabeth ;

Koeppler, Hubert ;

Kiehl, Michael ;

Soekler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Koechling, Georg ;

Ploeger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Trneny, Marek ;

Fischer, Kirsten ;

Doehner, Harmut ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Boettcher, Sebastian ;

Hallek, Michael .

LANCET ONCOLOGY, 2016, 17 (07) :928-942

[25] Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study) [J].

Eichhorst, Barbara F. ;

Bahlo, Jasmin ;

Maurer, Christian ;

Lange, Elisabeth ;

Koppler, Hubert ;

Kiehl, Michael G. ;

Sokler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Kochling, Georg ;

Ploger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Herling, Marco ;

Fischer, Kirsten ;

Dohner, Hartmut ;

Kneba, Michael ;

Wendtner, Clemens ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Bottcher, Sebastian ;

Stilgenbauer, Stephan ;

Fink, Anna Maria ;

Hallek, Michael .

BLOOD, 2016, 128 (22)

[26] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia [J].

Eichhorst, BF ;

Busch, R ;

Hopfinger, G ;

Pasold, R ;

Hensel, M ;

Steinbrecher, C ;

Siehl, S ;

Jäger, U ;

Bergmann, M ;

Stilgenbauer, S ;

Schweighofer, C ;

Wendtner, CM ;

Döhner, H ;

Brittinger, G ;

Emmerich, B ;

Hallek, M .

BLOOD, 2006, 107 (03) :885-891

[27] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions [J].

Fischer, K. ;

Al-Sawaf, O. ;

Bahlo, J. ;

Fink, A. -M. ;

Tandon, M. ;

Dixon, M. ;

Robrecht, S. ;

Warburton, S. ;

Humphrey, K. ;

Samoylova, O. ;

Liberati, A. M. ;

Pinilla-Ibarz, J. ;

Opat, S. ;

Sivcheva, L. ;

Du, K. Le ;

Fogliatto, L. M. ;

Niemann, C. U. ;

Weinkove, R. ;

Robinson, S. ;

Kipps, T. J. ;

Boettcher, S. ;

Tausch, E. ;

Humerickhouse, R. ;

Eichhorst, B. ;

Wendtner, C. -M. ;

Langerak, A. W. ;

Kreuzer, K. -A. ;

Ritgen, M. ;

Goede, V. ;

Stilgenbauer, S. ;

Mobasher, M. ;

Hallek, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) :2225-2236

[28] Venetoclax and obinutuzumab in chronic lymphocytic leukemia [J].

Fischer, Kirsten ;

Al-Sawaf, Othman ;

Fink, Anna-Maria ;

Dixon, Mark ;

Bahlo, Jasmin ;

Warburton, Simon ;

Kipps, Thomas J. ;

Weinkove, Robert ;

Robinson, Sue ;

Seiler, Till ;

Opat, Stephen ;

Owen, Carolyn ;

Lopez, Javier ;

Humphrey, Kathryn ;

Humerickhouse, Rod ;

Tausch, Eugen ;

Frenzel, Lukas ;

Eichhorst, Barbara ;

Wendtner, Clemens-M. ;

Stilgenbauer, Stephan ;

Langerak, Anton W. ;

van Dongen, Jacque J. M. ;

Boettcher, Sebastian ;

Ritgen, Matthias ;

Goede, Valentin ;

Mobasher, Mehrdad ;

Hallek, Michael .

BLOOD, 2017, 129 (19) :2702-2705

[29] Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial [J].

Fischer, Kirsten ;

Bahlo, Jasmin ;

Fink, Anna Maria ;

Goede, Valentin ;

Herling, Carmen Diana ;

Cramer, Paula ;

Langerbeins, Petra ;

von Tresckow, Julia ;

Engelke, Anja ;

Maurer, Christian ;

Kovacs, Gabor ;

Herling, Marco ;

Tausch, Eugen ;

Kreuzer, Karl-Anton ;

Eichhorst, Barbara ;

Boettcher, Sebastian ;

Seymour, John F. ;

Ghia, Paolo ;

Marlton, Paula ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Doehner, Hartmut ;

Stilgenbauer, Stephan ;

Hallek, Michael .

BLOOD, 2016, 127 (02) :208-215

[30] Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group [J].

Fischer, Kirsten ;

Cramer, Paula ;

Busch, Raymonde ;

Boettcher, Sebastian ;

Bahlo, Jasmin ;

Schubert, Joeerg ;

Pflueger, Karl H. ;

Schott, Silke ;

Goede, Valentin ;

Isfort, Susanne ;

von Tresckow, Julia ;

Fink, Anna-Maria ;

Buehler, Andreas ;

Winkler, Dirk ;

Kreuzer, Karl-Anton ;

Staib, Peter ;

Ritgen, Matthias ;

Kneba, Michael ;

Doehner, Hartmut ;

Eichhorst, Barbara F. ;

Hallek, Michael ;

Stilgenbauer, Stephan ;

Wendtner, Clemens-Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3209-3216

← 1 2 3 4 5 6 7 →